Cochrane Review Group

Metabolic and Endocrine Disorders

84 systematic reviews in Metabolic and Endocrine Disorders ask 1,105 questions. 39.3% have no studies to answer them, 22.3% rest on very low certainty evidence and 14.1% reach moderate or high certainty.

Reviews

Questions

1,105

current versions

No studies

39.3%

Moderate or high

14.1%

No studies 434 · 39.3%Ungraded 32 · 2.9%Very low 246 · 22.3%Low 237 · 21.4%Moderate 132 · 11.9%High 24 · 2.2%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Metabolic and Endocrine Disorders

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Intervention NR Health‐related quality of life · participants living with overweight or obesity Calcium supplementation for people with overweight or obesity (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR All‐cause mortality · participants living with overweight or obesity Calcium supplementation for people with overweight or obesity (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Morbidity · participants living with overweight or obesity Calcium supplementation for people with overweight or obesity (2024) · Cochrane	no estimate extracted	NR	No studies
Testosterone vs placebo Sexual quality of life · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane	no estimate extracted	NR	No studies
Testosterone vs placebo Cardiovascular mortality · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane	no estimate extracted	NR	No studies
Testosterone vs placebo Treatment withdrawal due to adverse events · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane	RR 1.04 [0.58, 1.86]	2 studies · 122 participants	Very low
Testosterone vs placebo Prostate‐related events · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane	no estimate extracted	NR	No studies
Testosterone vs placebo Lower urinary tract symptoms · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane	no estimate extracted	NR	No studies
Testosterone vs PDE5I Erectile function · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane	no estimate extracted	1 study · 64 participants	Very low
Testosterone vs PDE5I Sexual quality of life · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane	no estimate extracted	1 study · 64 participants	Very low
Testosterone vs PDE5I Cardiovascular mortality · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane	no estimate extracted	NR	No studies
Testosterone vs PDE5I Treatment withdrawal due to adverse events · men with sexual dysfunction Testosterone replacement in men with sexual dysfunction (2024) · Cochrane	no estimate extracted	NR	No studies

Reviews 84

Calcium supplementation for people with overweight or obesity

Cormick, G, Ciapponi, A, et al. · Cochrane Database of Systematic Reviews · 2024

Metabolic and Endocrine Disorders

Thinnest evidence

Reviews 84

Calcium supplementation for people with overweight or obesity

Testosterone replacement in men with sexual dysfunction

Surgical and non‐surgical interventions for primary and salvage treatment of growth hormone‐secreting pituitary adenomas in adults

Mobile health (m‐health) smartphone interventions for adolescents and adults with overweight or obesity

Low glycaemic index or low glycaemic load diets for people with overweight or obesity

Perioperative glycaemic control for people with diabetes undergoing surgery

Parathyroidectomy for adults with primary hyperparathyroidism

Interventions for people with type 2 diabetes mellitus fasting during Ramadan

Obesity as an independent risk factor for COVID‐19 severity and mortality

Thermal stability and storage of human insulin

Surgery for the treatment of obesity in children and adolescents

Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus

Screening for type 2 diabetes mellitus

(Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus

Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules

Minimally invasive parathyroidectomy guided by intraoperative parathyroid hormone monitoring (IOPTH) and preoperative imaging versus bilateral neck exploration for primary hyperparathyroidism in adults

Resveratrol for adults with type 2 diabetes mellitus

Vitamin D, calcium or a combination of vitamin D and calcium for the treatment of nutritional rickets in children

Non‐nutritive sweeteners for diabetes mellitus

Metformin monotherapy for adults with type 2 diabetes mellitus

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus

Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus

Oxandrolone for growth hormone‐treated girls aged up to 18 years with Turner syndrome

Fluoxetine for adults who are overweight or obese